Worldwide Adoptive Cell Therapy Industry to 2030 – Featuring Novartis, Gilead Sciences and Cellectis Among Others – ResearchAndMarkets.com – Yahoo…

DUBLIN, April 25, 2022--(BUSINESS WIRE)--The "Adoptive Cell Therapy Market, by Type, By Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells.

Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.

Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period.

Key features of the study:

This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global adoptive cell therapy market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market

Story continues

Market Segmentation:

Global Adoptive Cell Therapy Market, By Type:

Global Adoptive Cell Therapy Market, By Application:

Global Adoptive Cell Therapy Market, By End User:

Hospitals

Cancer Treatment Centers

Global Adoptive Cell Therapy Market, By Region:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

Europe

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

GCC

Israel

Rest of Middle East

Africa

South Africa

Central Africa

North Africa

Company Profiles

Novartis AG.

Gilead Sciences, Inc.

Castle Creek Biosciences, Inc

Lineage Cell Therapeutics, Inc.

Transgene SA

Cellectis

ImmunityBio, Inc

Sorrento Therapeutics

bluebird bio, Inc.

Arcellx

Sana Biotechnology, Inc.

Biodesix, Inc

Laurus Labs

For more information about this report visit https://www.researchandmarkets.com/r/kffwgd

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005562/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original here:
Worldwide Adoptive Cell Therapy Industry to 2030 - Featuring Novartis, Gilead Sciences and Cellectis Among Others - ResearchAndMarkets.com - Yahoo...